Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Imatinib Teva

Imatinib Teva 100 mg film-coated tablets Imatinib Teva 400 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15–16

HOS-218633 · Präparat HOS-216223

15 (platelet count < 10 x 109/l) were observed in 3.6% and < 1% of patients, respectively. The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively. These events can usually be managed with either a reduction of the dose or an interruption of treatment with imatinib, but can in rare cases lead to permanent discontinuation of treatment. In paediatric CML patients the most frequent toxicities observed were grade 3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia. These generally occur within the first several months of therapy.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.